# Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

> **NCT01253096** · PHASE2 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 25 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Intratumoral injections of L19IL2

## Key facts

- **NCT ID:** NCT01253096
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253096, "Intratumoral Application of L19IL2 in Patients With Malignant Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01253096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*